Spherics Frequently Asked Questions (FAQ)
When was Spherics founded?
Spherics was founded in 1997.
Where is Spherics's headquarters?
Spherics's headquarters is located at 375 Forbes Boulevard, Mansfield.
What is Spherics's latest funding round?
Spherics's latest funding round is Series C.
How much did Spherics raise?
Spherics raised a total of $40.48M.
Who are the investors of Spherics?
Investors of Spherics include CB Health Ventures, Zero Stage Capital, Pod Investment, Eastman, Advent International and 8 more.
Who are Spherics's competitors?
Competitors of Spherics include Chiasma, Sagent Pharmaceuticals, Catalent, Quinnova Pharmaceuticals, Glide Pharma and 12 more.
Compare Spherics to Competitors
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products.
Glide Pharma, formerly Caretek Medical, is a specialty pharmaceutical company developing products for easy, safe and convenient delivery of pharmaceuticals and vaccines using its Glide SDI - the Solid Dose Injector. By being much less invasive than traditional injection methods, Glide improves the treatment experience of both patients and carers and, by allowing the injection of solid formulations, opens up a wide range of therapeutic options for new and existing treatments.
MedManage Systems, Inc. aims to provide drug sampling solutions. The company's OmniSampleSM Solution aims to allow pharmaceutical companies to intensify physician use of trial medications, thereby increasing product revenues.
utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.ï¿½MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
FORMAC is a pharmaceutical R&D company engaged in drug delivery and development. The firm aims to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.